Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay
| Autor: | Andrew G. Bosanquet, A. G. Smith, Jenny A. Orchard, S. A. Johnson, S. J. Povey, J. A. Copplestone, David Oscier |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Oncology
Drug medicine.medical_specialty Chemotherapy Pathology Lymphocytic leukaemia Differential staining business.industry Chronic lymphocytic leukemia medicine.medical_treatment media_common.quotation_subject Hematology medicine.disease Internal medicine medicine Cytotoxicity Cladribine business Ex vivo media_common medicine.drug |
| Zdroj: | British Journal of Haematology. 106:474-476 |
| ISSN: | 0007-1048 |
| DOI: | 10.1046/j.1365-2141.1999.01581.x |
| Popis: | The ability to identify non-responders to cytotoxic chemotherapy has significant clinical and economic benefits. Differential staining cytotoxicity (DiSC) assays were performed in 34 previously treated patients with chronic lymphocytic leukaemia prior to treatment with cladribine. Of the 28 identified as ex vivo sensitive, 26 achieved a complete (CR) or partial response (PR) (median length of response 1.5 years, median survival 3.37 years) and two had a >70% fall in lymphocytes: six identified as ex vivo resistant failed to respond. The DiSC assay can accurately identify a subgroup of patients resistant to cladribine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text